Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Claims It’s On Pace To Traverse Its Patent Cliff, Meet Financial Guidance Through 2014

This article was originally published in The Pink Sheet Daily

Executive Summary

As it prepares for the U.S. patent expiration of blockbuster antidepressant Cymbalta later this year, Lilly says it is meeting three strategic priorities it set in 2009, putting it on a path to return to sustainable growth.

You may also be interested in...



Lilly Gives Investors A Glimpse At Post-2014 Balance Sheet

Eli Lilly says R&D and SG&A spending will decline as a percent of sales post-2014, likely resulting in spending cuts, when the company expects to return to sales growth after cycling through important patent losses.

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

Related Companies

UsernamePublicRestriction

Register

PS074853

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel